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Targeting IL-6 by both passive or active
immunization strategies prevents
bleomycin-induced skin fibrosis
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Hadley Mouhsine1, Hervé Do4, Jean-François Zagury1† and Yannick Allanore2,3†
Abstract
Introduction: Interleukin-6 (IL-6) is a pleiotropic cytokine for which preliminary data have suggested that it might
contribute to systemic sclerosis (SSc). Our aims were to investigate, firstly, IL-6 expression in patients with SSc and,
secondly, the efficacy of both passive and active immunization against IL-6 to reduce skin fibrosis in complementary
mouse models of SSc.
Methods: Human serum levels and skin expression of IL-6 were determined by enzyme-linked immunosorbent assay
and immunohistochemistry, respectively. We first evaluated the antifibrotic properties of the monoclonal anti-IL-6R
antibody, MR16-1, in the bleomycin-induced dermal fibrosis mouse model, reflecting early and inflammatory stages of
SSc. Then, we assessed the efficacy of MR16-1 in tight skin-1 (Tsk-1) mice, an inflammation-independent model of skin
fibrosis. Additionally, we have developed an innovative strategy using an anti-IL-6 peptide-based active immunization.
Infiltrating leukocytes, T cells, and B cells were quantified, and IL-6 levels were measured in the serum and lesional skin
of mice after passive or active immunization.
Results: Serum and skin levels of IL-6 were significantly increased in patients with early SSc. Treatment with MR16-1
led in the bleomycin mouse model to a 25% (P = 0.02) and 30% (P = 0.007) reduction of dermal thickness
and hydroxyproline content, respectively. MR16-1 demonstrated no efficacy in Tsk-1 mice. Thereafter, mice
were immunized against a small peptide derived from murine IL-6 and this strategy led in the bleomycin model to a
20% (P = 0.02) and 25% (P = 0.005) decrease of dermal thickness and hydroxyproline content, respectively. Passive and
active immunization led to decreased T-cell infiltration in the lesional skin of mice challenged with bleomycin. Upon
bleomycin injections, serum and skin IL-6 levels were increased after treatment with MR16-1 and were significantly
reduced after anti-IL-6 active immunization.
Conclusions: Our results support the relevance of targeting IL-6 in patients with early SSc since IL-6 is overexpressed
in early stages of the disease. Targeting IL-6 by both passive and active immunization strategies prevented
the development of bleomycin-induced dermal fibrosis in mice. Our results highlight the therapeutic potential
of active immunization against IL-6, which is a seductive alternative to passive immunization.
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Introduction
Systemic sclerosis (SSc, scleroderma) is a connective tis-
sue disease of unknown etiology that affects particularly
the skin. Early stages of SSc are characterized by vascular
changes and inflammatory infiltrates in the lesional skin
[1]. Later stages of SSc are characterized by an excessive
accumulation of extracellular matrix components, includ-
ing collagen, leading to increased skin thickness.
Several lines of evidence suggest a pathologic role of
cytokine overproduction in the pathogenesis of SSc, par-
ticularly in fibroblast activation, collagen synthesis, and
subsequent fibrosis. Interleukin-6 (IL-6) is a pleiotropic
cytokine whose activities stimulate the proliferation and
differentiation of B and T lymphocytes, enhance anti-
body production, activate T cells, stimulate hematopoietic
precursors to differentiate, influence the proliferative cap-
acity of non-lymphoid cells, and activate acute-phase pro-
tein response [2]. Preliminary data suggest that IL-6 might
contribute to human SSc: levels of IL-6 are increased in
the serum and in the lesional skin of patients with SSc,
spontaneous production of IL-6 by peripheral blood leu-
kocytes from patients with SSc is elevated compared with
healthy controls, and IL-6 levels correlate with skin thick-
ness score [3-12]. In addition, two preliminary reports
have showed that passive immunization with anti-IL-6
receptor (IL-6R) monoclonal antibody may alleviate skin
disease in two mouse models of inflammation-driven der-
mal fibrosis [13,14]. However, the anti-fibrotic properties
of IL-6 inhibition have not yet been assessed in mouse
models of SSc that reflect later and non-inflammatory
stages of SSc. Moreover, molecular targeted inhibition of
IL-6 signaling in vivo was restricted to passive immu-
nization, which may present several drawbacks, including
primary and secondary resistances, repeated injections,
side effects, and prohibitive costs. As an alternative and
innovative strategy, our group has developed peptide-
based anti-cytokine active immunization, which con-
sists in inducing autoantibodies through an immunization
against peptides of cytokines linked to a carrier pro-
tein (for example, keyhole limpet hemocyanin, or KLH)
[15-17]. This promising strategy has not been used so far
for IL-6 but has been successfully established for other cy-
tokines, including tumor necrosis factor-alpha (TNFα)
and IL-1β and IL-23 in different autoimmune diseases
[15-18]. Therefore, in this study, our aim was to com-
pare the antifibrotic properties of both passive and active
immunization against IL-6 in complementary mouse
models of SSc.
Materials and methods
Human skin biopsies
Paraffin-embedded sections of lesional skin biopsies were
obtained from 10 patients with SSc and five healthy age-
and sex-matched healthy volunteers. The median age of
patients with SSc (eight females and two males) was 55
years (range 39 to 65 years), and disease duration was 4.5
years (range 1 to 12 years). Five patients with SSc had a
disease duration of less than 5 years; four had the diffuse
cutaneous subset, and six had the limited. No patient
was treated with immunosuppressive or other potentially
disease-modifying drugs. The median age of controls (four
females and one male) was 57 years (range 31 to 62 years).
All of the study aspects were approved by the local ethics
review committee (Comité Consultatif de Protection des
Personnes dans la Recherche Biomédicale Paris Ile de
France III), and written informed consent was obtained
from all patients and controls [9,19,20].
Animals
Four- and six-week-old male and female DBA/2 strain
(Janvier, Le Genest Saint Isle, France) and five-week-old
male and female tight skin-1 (Tsk-1) strain (The Jackson
Laboratory, Bar Harbor, ME, USA) were bred and main-
tained at the animal care facilities of Montrouge dental
university (Montrouge, France). All experimental proce-
dures were conducted in compliance with animal health
regulations, and the local ethics committee approved
all animal experiments (Comité National de Réflexion
Ethique sur l’Expérimentation Animale-34).
Induction of bleomycin-induced dermal fibrosis
Skin fibrosis was induced in 6-week-old DBA/2 mice by
administering local injections of bleomycin for 3 weeks
(d0 to d21), as previously described [8,9,21]. Briefly,
100 μL of bleomycin dissolved in 0.9% NaCl at a con-
centration of 0.5 mg/mL was administered every other
day by subcutaneous injection into defined areas of 1 cm2
on the upper back for 3 weeks. Subcutaneous injections of
100 μL of 0.9% NaCl were used as negative control.
Tight skin mouse model
The Tsk-1 phenotype is caused by a dominant mutation
in the fibrillin-1 gene [22]. Tsk-1 mice are characterized
by accumulation of collagen fibers in the hypodermis
resulting in progressive hypodermal thickening. In con-
trast to bleomycin-induced fibrosis, inflammatory infil-
trates are absent and the aberrant activation of fibroblasts
is not caused by the release of inflammatory mediators
from leukocytes. Similar to SSc fibroblasts, fibroblasts
from Tsk-1 are endogenously activated with increased re-
lease of collagen that persists for several passages in vitro.
Anti-IL-6 receptor monoclonal antibody treatment
Rat anti-mouse IL-6 receptor monoclonal antibody (clone
MR16-1) described previously was provided by Chugai
Pharmaceutical (Tokyo, Japan) [13,23]. Purified rat IgG1
(isotype-matched control antibody, MP Biomedicals,
Illkirch, France) was administered as a negative control.
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DBA/2 mice received, in parallel of bleomycin injections,
an intraperitoneal (i.p.) injection of 2 mg at day 0 followed
by one i.p. injection of 1 mg at days 7 and 14. Mice were
sacrificed at day 21. Tsk-1 mice received a first i.p. injec-
tion of 2 mg at the age of 5 weeks followed by one i.p. in-
jection of 1 mg once a week. Mice were sacrificed by
cervical dislocation at the age of 10 weeks.
Selection of the peptide derivative of mouse IL-6
At the beginning of the study, no structural data on
mouse IL-6 were available. Peptide was designed by
using the human IL-6/IL-6Rα/gp130 structure (Protein
Data Bank (PDB) code: 1P9M). We could assume that
the chosen site was transposable to mIL-6 because of
the high conservation between mIL-6 and hIL-6 amino
acid sequences. This hypothesis was verified after the
publication of the mIL-6 structure in 2012 (PDB code:
2L3Y). Peptide was chosen in a loop exposed to the pro-
tein surface, which corresponded to a region involved in
the interaction between the cytokine IL-6 and its recep-
tor IL-6Rα.
Peptides synthesis and cyclisation
Peptides were synthesized by PolyPeptide Laboratories
(Strasbourg, France). Peptides were analyzed by high-
pressure liquid chromatography and mass spectrometry.
Only fractions with purity superior to 85% were con-
served. mIS200 peptide was produced in a cyclized form
by the formation of intramolecular disulphide bonds be-
tween cysteine residues.
Coupling of the peptide to the carrier protein
To ensure a specific coupling of the mIS200 peptide
to KLH, an additional tyrosine residue was added at its C-
terminus extremity before proceeding to the coupling with
bis-diazobenzidine (BDB). Briefly, the free amines of the
peptide were protected with citraconic acid at pH 8.5
to 9. Then, the peptide, the KLH, and a solution of
BDB were mixed together in a borate buffer for 2 hours at
4°C. The coupled peptide was then submitted to two dia-
lyses against 5% acetic acid followed by four dialyses
against phosphate-buffered saline (PBS). mIS200 se-
quence: Acétyl+C76MNNDDALAENNLKLPE92CY.
Immunizations with mIS200 peptide
DBA/2 mice were immunized four times by intramus-
cular injections with mIS200 peptide (100 μg/mouse) or
KLH alone (200 μg/mouse). The primo-injection was com-
pleted with complete Freund adjuvant (Sigma-Aldrich,
Saint-Quentin Fallavier, France) and the three boosters,
with an interval of 15 days, with incomplete Freund adju-
vant (Sigma-Aldrich). Immunizations were performed 31,
17, and 3 days before the first injection of bleomycin and
11 days after the first injection of bleomycin.
Mouse anti-IL-6 antibody ELISAs
Serum samples were obtained from mice at sacrifice,
and the IgG response against mouse IL-6 was measured
by enzyme-linked immunosorbent assay (ELISA). Briefly,
50 ng of mouse IL-6 (R&D Systems, Lille, France) was
adsorbed on microtitration plates overnight. After a step
of saturation, sera from immunized mice were serially
diluted in PBS bovine serum albumin 1% and added in
coated wells. A wash was followed by an incubation with
polyclonal anti-mouse IgG as secondary antibodies cou-
pled to horseradish peroxidase. Plates were revealed with
tetramethylbenzidine, and the reaction was stopped with
1 M sulfuric acid before reading on a spectrophotometer
(Multiskan Ex, Thermo Scientific) at 450 nm. ELISA ti-
ters were expressed as those serum dilutions that lead to
half-maximal optical density 450 (OD450) (titer50).
Evaluation of dermal and hypodermal thickness
Lesional skin areas were excised, fixed in 4% formalin,
and embedded in paraffin. Sections (5 μm thick) were
stained with hematoxylin and eosin. The dermal thick-
ness was analyzed at 100-fold magnification by measur-
ing the distance between the epidermal-dermal junction
and the dermal-subcutaneous fat junction at four sites
from lesional skin of each mouse. The hypodermal thick-
ness in Tsk-1 mice was determined by measuring the
thickness of the subcutaneous connective tissue beneath
the panniculus carnosus at four different sites of the
upper back in each mouse [8]. Two independent exam-
iners performed the evaluation.
Collagen measurements
The collagen content in lesional skin samples was evalu-
ated by the hydroxyproline assay [24]. After digestion of
punch biopsy specimens (3 mm diameter) in 6 M HCl
for 3 hours at 120°C, the pH of the samples was ad-
justed to 7. Afterwards, samples were mixed with 0.06 M
chloramine T and incubated for 20 minutes at room
temperature. Then, 3.15 M perchloric acid and 20% p-
dimethylaminobenzaldehyde were added, and samples
were incubated for an additional 20 minutes at 60°C. The
absorbance was determined at 557 nm with a spectropho-
tometer. For direct visualization of collagen fibers, tri-
chrome staining was performed.
Immunohistochemical analysis of α-SMA, CD3, CD22, IL-6,
and IL-6-R
Myofibroblasts were identified by staining for α-smooth
muscle actin (α-SMA), as previously described [8,9,21].
Cells positive for α-SMA in mouse skin sections were
detected by incubation with monoclonal anti-α-SMA anti-
body (clone 1A4; Sigma-Aldrich, Saint-Quentin Fallavier,
France) diluted 1:1,000 for 3 hours at room tempe-
rature. Polyclonal rabbit anti-mouse antibodies labeled
Desallais et al. Arthritis Research & Therapy 2014, 16:R157 Page 3 of 12
http://arthritis-research.com/content/16/4/R157
with horseradish peroxidase (Dako, Les Ulis, France)
were used as secondary antibodies for 1 hour at room
temperature. The number of myofibroblasts was deter-
mined at 200-fold magnification in six different sections
from each mouse by two blinded examiners.
To quantify the numbers of infiltrating T and B cells,
lesional skin sections were stained for CD3 and CD22,
respectively. Skin sections were incubated with poly-
clonal rabbit anti-human antibodies for CD3 or CD22
(Abcam, Paris, France). Polyclonal horseradish goat anti-
rabbit antibodies labeled with horseradish peroxidase
(Dako) were used as secondary antibodies. T and B cells
were counted in a blinded manner, by two examiners, in
six different sections of lesional skin of each mouse at
400-fold magnification.
To detect human IL-6 in lesional skin tissue, skin
sections were incubated with monoclonal mouse anti-
human antibodies against IL-6 (Abcam). Polyclonal rab-
bit anti-mouse antibodies labeled with horseradish
peroxidase (Dako) were used as secondary antibodies.
To detect mouse IL-6R in lesional skin tissue, poly-
clonal goat anti-mouse antibodies against IL-6R (R&D
Systems) were used. The intensity of immunostaining
was quantified with ImageJ software, as described in
the following webpage [25].
IL-6 measurement in lesional skin samples of bleomycin
treated mice
IL-6 levels were measured in the skin of mice injected
with bleomycin or NaCl by multiplex bead array tech-
nology (BD Biosciences, Le Pont de Claix, France), as
previously described [8,9].
Serum levels of IL-6 and IL-6R
Serum concentrations of IL-6 (pg/mL) and IL-6R (pg/mL)
were measured in a previously described cohort of 187
patients with SSc and 48 unrelated age/sex-matched sub-
jects by quantitative sandwich ELISAs (R&D Systems,
Minneapolis, MN, USA) in accordance with the recom-
mendations of the manufacturer [26]. Serum levels of IL-6
were also measured in mice subjected to bleomycin injec-
tions and passive or active immunization as well as in
their respective controls by using a U-cytech sandwich
mouse IL-6 ELISA kit (U-cytech Biosciences, Utrecht, The
Netherlands).
Statistics
Results were expressed as dot blots with median(Q1,Q3).
Mann-Whitney U test for non-related samples was used
for statistical analyses. P values of less than 0.05 were
considered significant.
Results
Serum levels and skin expression of IL-6 are increased in
patients with early systemic sclerosis
We first evaluated IL-6 and IL-6R expression in the
serum of 187 patients with SSc as compared with 48
healthy controls. Higher median IL-6 serum concentra-
tions were measured in patients with SSc compared with
controls, although not reaching significant threshold (5.6
versus 4.0 pg/mL, P = 0.09) (Figure 1A). In the subset of
patients with early disease (disease duration less than 5
years), median IL-6 serum levels were significantly
higher than in controls (5.8 versus 4.0 pg/mL, P = 0.006)
(Figure 1A). No difference was observed between SSc
and controls regarding IL-6R serum levels (data not
shown).
We next assessed skin expression of IL-6 by immuno-
histochemistry in patients with SSc and controls. Con-
sistent with the results obtained in serum, we observed
overexpression of IL-6 in the skin of patients with SSc,
including those with early disease (disease duration of
less than 5 years) (Figures 1B-E). The expression of IL-6
was detectable in the 10 patients with SSc and in the five
controls. Positive staining for IL-6 was observed in the
epidermis and in several cell types in the dermis, inclu-
ding perivascular inflammatory cells, fibroblasts, and
endothelial cells (Figures 1B and 1C). Moreover, the
amount of immunostaining was more abundant in pa-
tients with SSc compared with controls (P = 0.008), in-
cluding those with early disease (P = 0.008) (Figures 1D
and 1E). Taken together, these data support overexpres-
sion of IL-6 in patients with early SSc.
MR16-1 prevents bleomycin-induced dermal fibrosis
MR16-1 treatment prevented the induction of bleomycin-
induced dermal fibrosis. Upon bleomycin injections, der-
mal thickness was reduced by 25% in mice treated with
MR16-1 compared with mice treated with the isotype
control (P = 0.02) (Figures 2A and 2B). Consistent with
decreased dermal thickening, reduced accumulation of
collagen upon bleomycin challenge was observed on
trichrome-stained skin sections of mice treated with
MR16-1 (Figure 2C). In addition, the hydroxyproline
content in lesional skin was decreased by 30% in mice
treated with MR16-1 compared with those treated
with the isotype control (P = 0.007) (Figure 2D). The
number of myofibroblasts upon challenge with bleo-
mycin was also significantly reduced by 45% in mice
treated with MR16-1 (P = 0.005) (Figure 2E).
MR16-1 exerts no antifibrotic effect in Tsk-1 mice
We next investigated whether treatment with MR16-1 may
also be effective in a non-inflammatory model of SSc. We
observed that Tsk-1 mice treated with MR16-1 showed no
reduction of hypodermal thickness (Figures 3A and 3B)
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and collagen content (Figure 3C) compared with those re-
ceiving the isotype control.
Active immunization against IL-6 in the bleomycin
mouse model
Immunization of mice with mIS200 peptide is well tolerated
Following the encouraging results obtained with MR16-1
in the prevention of bleomycin-induced dermal fibrosis,
we aimed to evaluate the protective effect of an anti-
IL-6 peptide-based active immunization in this model.
Immunization of mice with mIS200 peptide at a dose
of 100 μg per injection was well tolerated. mIS200-
immunized mice appeared healthy with normal activ-
ity, behavior, and texture of the fur. The body weight
also did not differ between mice treated with mIS200
and KLH-immunized control.
Figure 1 Interleukin-6 (IL-6) is overexpressed in the serum and the skin of patients with systemic sclerosis (SSc). (A) Patients with SSc
and early disease (less than 5 years) had increased IL-6 serum levels compared with age- and sex-matched healthy controls (P = 0.006). IL-6 was
detected ex vivo by immunohistochemistry in patients with SSc (C) compared with controls (B). Positive staining for IL-6 was observed in the
epidermis and in several cell types of the dermis. In addition, the intensity of immunostaining assessed by the ImageJ software was significantly
increased in patients with SSc compared with controls (P = 0.0007) (D), particularly in those with early disease (P = 0.008) (E). Bars
represent median(Q1,Q3).
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Anti-IL-6 autoantibody production
DBA/2 mice were immunized four times with mIS200
peptide, and bleomycin-induced fibrosis was induced
after the second booster injection. Anti-IL-6 antibody
production was evaluated by ELISA at sacrifice. Mice
immunized against mIS200 peptide produced a high level
of autoantibodies against IL-6, whereas mice immunized
against KLH alone did not exhibit anti-IL-6 antibodies
(Figure 4). All mice showed antibody response to the car-
rier protein KLH (data not shown).
Anti-IL-6 peptide-based active immunization alleviates
bleomycin-induced skin fibrosis
Mice immunized against the mIS200 peptide exhibited a
significant reduction of dermal thickness by 20% com-
pared with the group immunized against KLH alone
(P = 0.02) (Figures 5A and 5B). Consistently with de-
creased dermal thickening, a significant reduction of
the collagen content following bleomycin challenge
was observed on trichrome-stained skin sections from
mice immunized against mIS200 peptide (Figure 5C).
Furthermore, the hydroxyproline content in the lesio-
nal skin of mIS200-immunized mice was significantly
decreased by 25% compared with the skin of KLH-
immunized mice (P = 0.005) (Figure 5D). In addition,
the number of myofibroblasts was decreased by 41%
in mIS200-immunized mice (P = 0.01) (Figure 5E).
Passive or active immunization against IL-6 reduce T-cell
infiltration in lesional skin
Inflammatory infiltrates are characteristic features of early
stages of SSc, which are mimicked in the bleomycin-
induced fibrosis mouse model. Infiltrating leukocytes con-
tain mostly T cells, with a perivascular distribution, and
stimulate fibroblast activation and collagen synthesis via
the release of pro-fibrotic factors [1]. To evaluate whether
passive or active immunization against IL-6 influences the
outcome of bleomycin-induced fibrosis by regulating leu-
kocyte infiltration, we quantified the number of leukocytes
in lesional skin. Inflammatory infiltrates upon bleo-
mycin treatment were significantly reduced in mice trea-
ted with MR16-1 or immunized against the mIS200
Figure 2 Mice treated with MR16-1 are protected against bleomycin-induced dermal fibrosis. (A) Reduced dermal fibrosis in mice treated
with MR16-1, injected with bleomycin. Representative hematoxylin and eosin-stained skin sections are shown. (B) Decreased dermal thickness in
mice treated with MR16-1 (change by median(Q1,Q3) 1.00.7,1.2 versus 1.11.0,1.5 fold, P = 0.02). (C) Reduced accumulation of collagen in mice treated
with MR16-1 following bleomycin treatment. Collagen fiber visualization by trichrome-staining skin sections is shown. (D) Reduced hydroxyprolin
content in mice treated with MR16-1 following bleomycin treatment (change by median(Q1,Q3) 1.10.9,1.4 versus 1.61.2,2.0 fold, P = 0.007). (E) Lower
myofibroblast counts in mice treated with MR16-1 following bleomycin treatment (change by median(Q1,Q3) 0.90.8,1.5 versus 1.51.3,2.5 fold, P = 0.005).
Control mice were injected with NaCl, and the value for these mice was defined as 1; the results from the other groups were normalized to this value.
Bars represent median(Q1,Q3); 36 mice were used for these experiments (12 per group). Ab, antibody.
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peptide compared with mice injected with isotype control
or KLH (P = 0.03 for both comparisons) (Figures 6A-D).
Since T cells are the main component of inflammatory in-
filtrates, we quantified the number of T cells in fibrotic
skin. Consistent with the reduced number of leukocytes,
T-cell counts were significantly lower in mice treated with
MR16-1 or immunized against the mIS200 peptide com-
pared with their respective control groups (P = 0.02 for
both comparisons) (Figures 6E and 6F). In contrast to T
cells, the number of B cells did not significantly differ
upon bleomycin challenge between mice treated with
MR16-1 or immunized against the mIS200 peptide and
those injected with isotype control or KLH (data not
shown).
Serum and skin levels of IL-6 are regulated by passive or
active immunization against IL-6
To better apprehend the effects of passive and active
immunization in the bleomycin-induced dermal fibrosis
mouse model, IL-6 and IL-6R expressions were assessed
in the lesional skin of mice by multiplex bead array tech-
nology and immunohistochemistry, respectively. In ad-
dition, serum levels of IL-6 were measured by ELISA.
Mice treated with MR16-1 and subjected to bleomycin
injections displayed significantly higher IL-6 serum levels
Figure 3 Tight skin-1 (Tsk-1) mice are not protected from skin fibrosis by MR16-1 treatment. (A, B) Tsk-1 mice showed increased hypodermal
thickness compared with the pa/pa control mice. However, no difference was observed between Tsk-1 mice receiving either MR16-1 or the isotype
control. (C) Tsk-1 mice showed increased hydroxyproline concentration compared with the pa/pa control mice. However, no difference was observed
between Tsk-1 mice receiving either MR16-1 or the isotype control. pa/pa mice (control mice for Tsk-1 mice) were defined as 1.0, and all other results
are normalized to this value. Bars represent median(Q1,Q3); 17 mice were used for these experiments (five pa/pa mice, four Tsk-1 mice treated with
isotype control, and eight Tsk-1 mice treated with MR16-1). Ab, antibody; NS, not significant.
Figure 4 Anti-mIL-6 autoantibody production in the group of
mice immunized against mIS200 peptide and in the groups of
mice immunized against keyhole limpet hemocyanin (KLH)
alone. No anti-IL-6 autoantibodies were detected in serum samples
from mice immunized against KLH alone compared with the mice
immunized against mIS200 peptide. Bars represent mean ±
standard deviation.
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than mice receiving the isotype control (Figure 7A), as
reported in previous publications [27]. Consistent with
this result, a trend for higher skin levels of IL-6 was ob-
served upon MR-16 treatment (Figure 7B). Upon bleo-
mycin challenge, IL-6 levels were significantly reduced
in the serum and the skin of mice immunized against
the mIS200 peptide compared with mice injected with
KLH (Figures 7C and 7D).
Dermal expression of IL-6R was not modified by pas-
sive or active immunization against IL-6 in mice chal-
lenged with bleomycin injections (data not shown).
Discussion
We first confirmed that IL-6 is overexpressed in the
serum and the skin of patients with SSc and particularly
in those with early disease. Since upregulation of serum
IL-6 has been shown to be associated in SSc with disease
activity, severity, disability, worse outcome, and reduced
survival, targeting IL-6 may be particularly relevant in pa-
tients with early disease. Our results in mice also confirm
the relevance of targeting IL-6 in early SSc since IL-6
exhibits a critical role in the development of bleomycin-
induced dermal fibrosis, which reflects early and inflam-
matory stages of SSc. Indeed, inhibition of IL-6 through
an innovative anti-IL-6 active immunization strategy exer-
ted similar antifibrotic properties as passive immunization
with MR16-1 (monoclonal antibody against IL-6-R) in the
bleomycin-induced dermal fibrosis mouse model, by redu-
cing the infiltration of inflammatory cells, especially T
cells, into lesional skin. Conversely, MR16-1 did not pre-
vent the development of fibrosis in the Tsk-1 mouse
model, suggesting that IL-6 has no direct effects on fibro-
blast activation and collagen synthesis in this model of late
and non-inflammatory stages of SSc.
We first performed passive immunization with MR16-1
in the bleomycin mouse model (i) to confirm previously
reported findings in our in-house bleomycin-challenged
mice and (ii) to obtain a range of effect of passive im-
munization efficacy, allowing further comparison with ac-
tive immunization. We showed that mice treated with
Figure 5 Mice immunized against mIS200 peptide are protected against bleomycin-induced dermal fibrosis. (A) Reduced dermal fibrosis
in mice immunized against mIS200 peptide injected with bleomycin. Representative hematoxylin and eosin-stained skin sections are shown. (B)
Decreased dermal thickness in mice immunized against mIS200 peptide treated with bleomycin (change by median(Q1,Q3) 1.21.1,1.4 versus 1.41.3,1.6
fold, P = 0.02). (C) Reduced accumulation of collagen in mice immunized against mIS200 peptide challenged with bleomycin. Collagen fiber
visualization by trichrome-staining skin sections is shown. (D) Reduced hydroxyprolin content in mice immunized against mIS200 peptide following
bleomycin treatment (change by median(Q1,Q3) 1.00.9,1.2 versus 1.41.1,1.6 fold, P = 0.005). (E) Lower myofibroblast counts in mice immunized against
mIS200 peptide following bleomycin treatment (change by median(Q1,Q3) 1.71.2,2.2 versus 2.41.7,3.6 fold, P = 0.01). Control mice were injected with NaCl,
and the value for these mice was defined as 1; the results from the other groups were normalized to this value. Bars represent median(Q1,Q3); 36 mice
were used for these experiments (nine in the group keyhole limpet hemocyanin (KLH) NaCl, 16 in the group mIS200 bleomycin, and 11 in the group
KLH bleomycin).
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MR16-1 were protected from the development of dermal
fibrosis, with a significant reduction of dermal thickness,
collagen content, and infiltrating myofibroblasts in the
lesional skin. Our results were in line to those of Kitaba
et al. [13], despite several differences in the experiments
performed. In particular, we used DBA/2 mice in our
study, which show higher susceptibility to bleomycin-
induced fibrosis than C57BL/6 mice [28]. Both studies
differed for the bleomycin injection protocol (bleomycin
at a concentration of 0.5 mg/mL injected subcutaneously
every other day for 3 weeks in our study compared with a
concentration of 1 mg/mL injected subcutaneously daily
for 4 weeks). We have used this protocol in several previ-
ous projects [8,9,21]. The treatment scheme with MR16-1
was also different between both studies (a first i.p. injec-
tion of 2 mg at day 0 then i.p. injections of 1 mg at days 7
Figure 6 Interleukin-6 (IL-6) regulates leukocyte and T-cell infiltration into lesional skin. (A, B) Reduced inflammation in mice treated with
MR16-1 or immunized against the mIS200 peptide and challenged with bleomycin. Representative sections stained by hematoxylin/eosin at
400-fold magnification. (C, D) Decreased leukocyte counts in lesional skin of mice treated with MR16-1 or immunized against the mIS200 peptide.
(E, F) Reduced number of CD3+ T cell by immunohistochemistry in lesional skin of mice treated with MR16-1 or immunized against the mIS200
peptide. Bars represent median(Q1,Q3); in regard to leukocyte quantification, 36 mice were evaluated for passive immunization and 36 for active
immunization. In regard to T-cell quantification, 15 randomly chosen mice (five per group) were evaluated for passive immunization as well as for
active immunization. All results are normalized to mice injected with NaCl. Ab, antibody; KLH, keyhole limpet hemocyanin.
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and 14 in our study compared with a first intravenous in-
jection of 2 mg at day 0 then i.p. injections of 0.5 mg at
days 7, 14, and 21) [13]. Our data showed that MR16-1
exerts antifibrotic effects in the model of bleomycin-
induced skin fibrosis by reducing the infiltration of T
cells into lesional skin, which was not reported before. Re-
duced T-cell infiltration may lead to decreased resident
fibroblast activation in lesional skin. This is consistent
with the reduction of myofibroblast counts in MR16-1-
treated mice, upon bleomycin challenge, observed in our
study and previously reported by Kitaba et al. [13].
We also observed a significant increase of serum IL-6
levels and a trend for increased skin IL-6 expression in
mice treated with MR16-1. This is in line with previous
observations of increased blood IL-6 levels after anti-
IL-6R antibody injection [27]. This elevation seems to
be the result of IL-6 clearance inhibition due to IL-6R
blockade, rather than induction of IL-6 synthesis to coun-
terbalance IL-6 blockade, or release of free IL-6 from
complexes [27].
Since previous studies focused on the effects of IL-6
inhibition with MR16-1 in mouse models of bleomycin-
induced dermal fibrosis, we next aimed to assess the
effect of MR16-1 in a non-inflammatory mouse model
of SSc. Thus, we investigated the effects of MR16-1 in
the Tsk-1 mouse model, in which increased serum IL-6
levels have been reported [7]. However, MR16-1-treated
mice did not exhibit a reduction of skin fibrosis, sug-
gesting that other pathways or cytokines may be more
important in this specific mouse model. This result also
supports that IL-6 exerts indirect profibrotic effects in
early inflammatory stages of SSc rather than by direct ef-
fects on the collagen synthesis by fibroblasts. This result
contrasts with the direct profibrotic effects of IL-6 ob-
served recently on dermal fibroblasts [29]. Since these
results were obtained in vitro in human fibroblasts, they
may differ from those obtained in vivo in the very spe-
cific Tsk-1 mouse model. The absence of antifibrotic ef-
fects of MR16-1 in the Tsk-1 mice is also sustained by
the controversial role of immune cells, especially T and
B cells, in the development of fibrosis in this mouse
model. Although a role for CD4+ T and B cells has been
suggested in the activation of collagen synthesis, bone
marrow transplantation experiments have challenged the
contribution of these immune cells [7,30]. Indeed, the
transfer of enriched B or T cells increased autoantibody
Figure 7 Passive and active immunizations against interleukin-6 (IL-6) regulate serum levels and skin expression of IL-6. (A, B) In mice
challenged by bleomycin, MR16-1 treatment led to a significant increase of IL-6 serum levels (P <0.0001) and a trend for increased IL-6 skin
expression (P = 0.08). (C, D) Immunization against the mIS200 peptide conducted to a significant reduction of IL-6 in the serum and in the skin
of mice challenged with bleomycin. Bars represent median(Q1,Q3); in total, 36 mice were evaluated for passive immunization and 36 for active
immunization. All results are normalized to mice injected with NaCl.
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production but did not cause skin fibrosis, and transfer
of T and B lymphocytes led only to mild fibrotic lesions
compared with massive fibrosis in Tsk-1 mice [31]. In
line with this finding, Tsk-1 mice lacking mature T and
B lymphocytes developed a fibrotic phenotype in the ab-
sence of a functional immune system [32]. Taken to-
gether, our results support that passive immunotherapy
with MR16-1 has interest only in inflammation-driven
dermal fibrosis; thus, this strategy should preferentially
be tested in early inflammatory stages of SSc.
Following our results obtained with MR16-1 in the
bleomycin mouse model, we evaluated the antifibrotic
effects of IL-6 inhibition with an innovative anti-
cytokine strategy. Since the late ’90s, anti-cytokine bi-
ologics (monoclonal antibodies and soluble receptors)
have successfully been used to treat chronic inflam-
matory diseases. However, these biotherapies present
several drawbacks, including primary and secondary
resistances, repeated injections, side effects, and pro-
hibitive costs. To circumvent these drawbacks, new
anti-cytokine strategies, such as the anti-cytokine active
immunization strategy, are in development [33]. This is
notably highlighted by the use of anti-TNFα kinoid in a
phase-2 trial in rheumatoid arthritis (ClinicalTrials.gov
identifier NCT01040715) and Crohn’s disease (Clinical-
Trials.gov identifier NCT01291810). In the present stu-
dy, mice immunized against an IL-6 peptide exhibited a
significant reduction of dermal fibrosis, collagen con-
tent, and myofibroblasts in the bleomycin mouse model
with no adverse event. Moreover, this prevention was
similar to the one conferred by the MR16-1 monoclonal
antibody (25% and 20% reduction of dermal thickness,
respectively, and 25% and 30% reduction of hydroxypro-
line content, respectively). Our results suggest that ac-
tive immunization against IL-6 displays antifibrotic
properties by decreasing T-cell infiltration into lesional
skin, similarly as passive immunization, and by reducing
IL-6 levels, as demonstrated by decreased IL-6 levels in
the serum and the skin of mice immunized against the
mIS200 peptide and challenged with bleomycin. This
work shows the feasibility and the efficacy of targeting
IL-6 by a peptide-based active immunization in order to
block endogenous IL-6 pathological effects. Of note,
this strategy was not evaluated in the Tsk-1 mouse
model regarding the negative results obtained with the
passive immunization strategy.
Evaluation of passive and active immunization was not
evaluated to reverse established fibrosis, which is a limi-
tation of our study. Kitaba et al. [13] have previously
shown that passive immunization with MR16-1 improves
established bleomycin-induced dermal fibrosis. Further
studies are required to assess whether active immuniza-
tion may be curative in the modified bleomycin model of
established dermal fibrosis.
Conclusions
Using complementary mouse models of SSc, we demon-
strated that passive and active immunization targeting
IL-6 had similar antifibrotic effects in the mouse model
of bleomycin-induced dermal fibrosis, which are medi-
ated by the reduction of T-cell infiltration into lesional
skin and by the decreased skin IL-6 levels in the case of
active immunization. Translation to human disease is
now required, and targeting early and inflammatory sta-
ges of SSc sounds the most appropriate. The passive
immunization strategy is under investigation in a phase-
3 clinical trial assessing the efficacy of tocilizumab to im-
prove skin involvement in patients with early diffuse SSc
(ClinicalTrials.gov identifier NCT01532869). Targeted in-
novative therapies are the most important issue in SSc,
which is a very severe condition free of an efficient drug.
It is awaited eagerly by the whole medical community, to-
gether with the patients, in order to stop the progression
of tissue damage by this devastating disease.
Our results also highlight the relevance of anti-IL-6
peptide-based active immunotherapy to treat autoimmune
diseases. Further investigations are needed to translate this
strategy into humans, but it constitutes a promising thera-
peutic approach.
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